Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma: Complete Statistical Analysis

1. Trial at a Glance

This page covers the registry results for Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma (NCT00901927), a na phase 2 study. The primary outcome is Complete Response Rate of the Combination of BMR (Bendamustine + Mitoxantrone + Rituximab).

2. Clinical Question

The central question is whether the combination can control disease in the specified study population, with complete response used as the primary measure of response. Under the International Working Group Criteria for Response for Non-Hodgkin's Lymphoma, complete response means disappearance of all detectable clinical evidence of disease and disease-related symptoms. This definition makes the endpoint a categorical clinical status rather than a measure of the degree of change in tumor burden.

Because the study has a single group, its primary question is descriptive: what response count was recorded among participants treated with BMR? It does not directly estimate a difference between BMR and another treatment or a control condition. The registry record does not report a complete-response count, rate, or uncertainty interval, so the outcome cannot be quantified from the record.

The study is listed as Phase II and terminated. The record gives enrollment as 14, but does not explain the relationship between enrollment and the group sizes listed in the adverse-event summary. The safety and time-to-progression outcomes are named, but their results are not reported in the registry record. These gaps limit how fully the clinical question can be answered from the posted information.

3. Trial Design

This is a Phase II, single-group study sponsored by M.D. Anderson Cancer Center. The registry lists allocation as not applicable and masking as none. The study is marked terminated. Its recorded start is 2009-05, and its primary completion is 2016-01. Enrollment is listed as 14.

The intervention is the combination of bendamustine, mitoxantrone, and rituximab. The arm description specifies bendamustine starting at 90 mg/m^2 intravenously over 30-60 minutes on Days 1 and 2 of each 8-day cycle; mitoxantrone at 10 mg/m^2 intravenously over 15 minutes on Day 2; and rituximab at 375 mg/m^2 intravenously over several hours on Day 1. These details describe the regimen in the record, not a comparison of alternative dosing strategies.

The primary outcome is the complete response rate of the combination, with a timeframe of 3 months. The registry describes complete response using International Working Group Criteria for Response for Non-Hodgkin's Lymphoma. The named secondary outcomes are participants with adverse events and time to progression for participants treated with BMR.

A single-group design can describe outcomes observed after treatment, but it does not create a concurrent control group for estimating a treatment contrast. The record does not report a comparator, randomization, or masking. Accordingly, differences against an untreated group or another therapy cannot be estimated from this design as recorded.

The registry lists 3 outcome measures and 0 analyses. That means the record contains outcome descriptions but no analysis entries. It does not establish whether analyses were conducted outside the registry. The protocol, recruitment details, reasons for termination, and statistical analysis plan are not reported in the registry record. The listed enrollment should not be assumed to be the denominator for every outcome, because outcome-specific participant counts are not given for the primary endpoint.

4. Participant Flow and Accounting

The registry reports how participants moved through each stage of the study. All counts below are exactly as posted; missing counts are not inferred from other stages.

Overall Study

Reasons for not completing this period:

5. Baseline Characteristics

The table reproduces the baseline characteristics posted in the registry, which describe the participants analysed at baseline and help show whether the randomized groups were comparable.

6. Primary Endpoint

The registry lists the primary outcome as Complete Response Rate of the Combination of BMR (Bendamustine + Mitoxantrone + Rituximab), measured over 3 months.

The primary endpoint is the complete response rate for the BMR combination, assessed at 3 months. The registry defines complete response according to International Working Group Criteria for Response for Non-Hodgkin's Lymphoma: complete disappearance of all detectable clinical evidence of disease and disease-related symptoms. It is a binary outcome at the participant level: a person either meets the stated response definition or does not.

A complete response endpoint is used to describe whether participants meet a clinically defined state after treatment, rather than to measure a continuous quantity such as the size of a change. In general, a response count and the number assessed can be used to estimate the proportion meeting the definition. The estimate's precision depends on the amount of information in the observed data; an uncertainty interval can express a range of values compatible with those data under a statistical method.

The registry record does not report the number with complete response, the number assessed for response, a response rate, or an uncertainty interval. It therefore does not permit a numerical description of the primary endpoint result. The listed enrollment of 14 is not enough to infer the endpoint denominator, response status, or missing response assessments.

The endpoint definition and timeframe are reported, but details such as the assessment schedule, handling of unevaluable participants, and analysis population are not reported in the registry record. Those details matter when interpreting a response proportion, particularly if some participants do not have an assessable response at the specified time.

7. Why No Re-analysis Is Shown

8. Statistical Interpretation

9. Statistical Methods Explained

Statistical interpretation starts with the design and the outcome scale. This study is recorded as a single-group Phase II trial with no masking. Its primary outcome is a participant count for complete response at 3 months. The record does not report a response count, denominator, or analysis, so a response proportion or its precision cannot be described from the posted results.

What does a single-group design estimate?

In general, a single-group study can estimate the frequency of an outcome among participants observed under the study regimen. It does not directly estimate what would have happened to the same population under a different regimen or no study treatment. A comparator group is needed for a direct between-group contrast, and the registry record does not list one. Differences from external experience would also require careful assumptions about whether populations, outcome definitions, follow-up, and measurement procedures are comparable; such an external comparison is not reported.

Allocation is listed as not applicable, consistent with the single-group model. Masking is listed as none. These design details do not establish how outcomes were assessed or whether assessors knew treatment status; that assessment detail is not reported in the registry record. In general, response assessments can be influenced by measurement procedures, so a clear assessment process is relevant when interpreting a categorical response outcome.

How should a binary response endpoint be understood?

Complete response is defined as complete disappearance of all detectable clinical evidence of disease and disease-related symptoms. For a binary endpoint, the basic descriptive result would identify how many participants met the definition and how many were assessed. A proportion summarizes the observed frequency, while a confidence interval gives a range of values compatible with the data under the chosen method. In general, wider intervals indicate less precision and narrower intervals indicate more precision. Neither the count nor an interval can be reconstructed from the registry entry, because the primary response data are not reported.

The endpoint timeframe is 3 months. In general, a timeframe specifies when response status is assessed and helps distinguish an early response measure from later outcomes. It does not by itself describe the assessment schedule, the treatment exposure required before assessment, or how participants without an assessment are classified. Those details are not reported in the registry record.

What does the analysis information establish?

The registry lists 0 analyses. This means no analysis records are present in the registry entry; it does not prove that no analysis was performed elsewhere. No statistical methods, confidence intervals, hypothesis tests, adjustment procedures, or analysis populations are described in the record. The statistical plan is not reported in the registry record, so no assumptions about a prespecified primary analysis or its handling of the outcome should be made.

The study lists 3 outcome measures. Having several outcomes raises a general interpretive issue: when many outcomes or comparisons are examined, the chance of at least one apparently unusual result can increase. Multiplicity methods can address that issue when appropriate, but the registry does not state whether any such methods were planned or used. Since no analysis results are reported, it is also not possible to determine which outcomes were analyzed or how their results were interpreted.

How do missing observations affect interpretation?

In general, missing outcome data can change the denominator and can bias an estimate if the probability of being observed is related to response status or other relevant factors. Analysts may use different approaches, but each relies on assumptions that should be made explicit. The record does not report the number with an assessable primary outcome, the amount or pattern of missing data, or a method for handling missing response assessments. Consequently, neither the completeness of the primary endpoint data nor the effect of missingness can be evaluated.

The enrollment entry is 14, while the adverse-event summary records 8 at risk and 8 affected for the combination group. The registry does not explain the relationship between those entries. In general, denominators can differ across outcomes because assessment eligibility, follow-up, or data availability differ; that is a general possibility, not an explanation established for this study. The record does not identify an analysis population that would clarify the discrepancy.

What is the status of the sample-size illustration?

The planning assumptions describe an illustration based on an observed effect, with a two-sided significance level of 0.05, equal allocation between two arms, and a normal approximation; the effect to detect is expressed as a stated fraction of the observed effect. Those assumptions are explicitly not described as the trial's own design. They should not be interpreted as the protocol's sample-size justification, a record of actual allocation, or evidence of observed power. In general, power calculations are planning exercises tied to assumptions about an effect and analysis; they do not establish the probability that a particular result is true. The registry record does not report the trial's sample-size justification or an observed effect for the primary endpoint.

The sample-size assumptions also describe different ways of expressing planning quantities for different outcome types. They do not supply missing primary endpoint observations. No planning illustration can replace the response count, denominator, or statistical analysis that would be needed to interpret the observed complete response result.

10. Exact Estimates for Each Arm

No two-arm comparison is shown for this trial, but each arm's result can still be summarized with exact interval estimates computed from the posted counts. The Clopper-Pearson interval is exact and conservative; the Wilson interval is a common closer-to-nominal alternative; the Bayesian credible interval uses a uniform Beta(1, 1) prior. For small groups the three can differ noticeably.

R code and output

arm    <- c("Bendamustine + Mitoxantrone + Rituximab")
n      <- c(8)
events <- c(3)
for (i in seq_along(n)) {
  ci <- binom.test(events[i], n[i])$conf.int          # Clopper-Pearson exact interval
  cr <- qbeta(c(0.025, 0.975), 1 + events[i], 1 + n[i] - events[i])   # Bayesian, uniform Beta(1,1) prior
  wi <- (function(x, n) { p <- x / n; z <- qnorm(0.975); d <- 1 + z^2 / n
    c((p + z^2 / (2 * n) - z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d, (p + z^2 / (2 * n) + z * sqrt(p * (1 - p) / n + z^2 / (4 * n^2))) / d) })(events[i], n[i])
  cat(sprintf("ARM|%s|%d|%d|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f|%.1f\n", arm[i], n[i], events[i], 100 * events[i] / n[i],
              100 * ci[1], 100 * ci[2], 100 * wi[1], 100 * wi[2], 100 * cr[1], 100 * cr[2]))
}

ARM  Bendamustine + Mitoxantrone + Rituximab  8  3  37.5  8.5  75.5  13.7  69.4  13.7  70.1

11. Multiplicity, Missing Data and Analysis Populations

The registry lists 3 outcome measures: complete response as the primary outcome, participants with adverse events, and time to progression. It lists 0 analyses. The outcome descriptions therefore identify several questions, but the record does not report results or analytical procedures for them.

When several outcomes are examined, general statistical practice distinguishes the primary question from secondary or exploratory questions and considers whether multiplicity adjustments are needed. Such adjustments can affect how uncertainty or statistical evidence is interpreted across multiple tests. The registry record does not report a multiplicity strategy, a hierarchy among analyses beyond naming a primary outcome, or whether any tests were conducted. No adjustment should be assumed.

Missing-data handling is also not reported in the registry record. The entry does not state how participants without a response assessment were treated, whether outcome-specific denominators differed, or whether any sensitivity analyses were planned. In general, excluding participants with missing outcomes can affect interpretation if missingness is related to the outcomes or to factors associated with them. Without the number assessed and the method used, the effect of missingness cannot be evaluated.

The record lists enrollment as 14, whereas the serious and other adverse-event summaries each list 8 at risk and 8 affected for the combination group. It does not explain this difference. The primary endpoint denominator and analysis population are not reported in the registry record. These entries should be read as outcome-specific information, not combined into a single inferred denominator.

The registry's 0 analysis entries do not show that no analyses were performed outside the record. They indicate that analysis methods and results are not documented in this registry entry. The planned statistical analysis, any deviations from it, and the treatment of incomplete follow-up are not reported.

12. Safety Results

The registry reports serious adverse events as affected participants divided by participants at risk.

Other (non-serious) adverse events

Participants with at least one non-serious event at or above the registry's 0% reporting threshold.

Most frequent serious adverse event terms

Most frequent non-serious adverse event terms

Serious events with the highest arm-level rate: leukopenia (100.0%), anc decrease (75.0%), dyspnea (37.5%), thrombocytopenia (37.5%), colitis (12.5%).

The registry's adverse-event summary lists the BMR group with 8 at risk and 8 affected for serious adverse events, and 8 at risk and 8 affected for other adverse events. The record does not explain how these counts relate to the enrollment entry of 14. The listed serious-event terms are leukopenia at 100.0%, ANC decrease at 75.0%, dyspnea at 37.5%, thrombocytopenia at 37.5%, colitis at 12.5%, and constipation at 12.5%.

These percentages describe the event terms as reported in the registry; they are not estimates of comparative risk because no control group is recorded. A serious adverse event is a safety classification, while the listed terms describe event types. The record does not provide the event counts behind each term, timing, duration, recurrence, or details of attribution. The listed percentages should therefore be read as a limited safety summary, not as a complete account of each participant's experience.

In general, safety percentages depend on the denominator and on how events are collected and coded. The registry does not provide enough detail to independently assess those procedures or reconcile the adverse-event group size with enrollment. Deaths are not reported in the registry record; this should not be interpreted as a reported count of zero.

13. What the Result Does, and Does Not, Mean

The record describes a Phase II, single-group study of bendamustine, mitoxantrone, and rituximab in untreated high-risk follicular lymphoma. It identifies complete response at 3 months as the primary endpoint, defines that response using International Working Group Criteria for Response for Non-Hodgkin's Lymphoma, and lists safety and time to progression as secondary outcomes. It also records selected serious adverse-event terms.

Those details explain the clinical question and the intended outcome framework, but the registry record does not report the primary response count, response rate, or an uncertainty interval. It therefore does not show how many participants met the complete response definition or how precisely any response frequency was estimated. The time-to-progression result is also not reported in the registry record.

Because the trial is single-group, the design does not provide a direct comparison with another treatment or a control condition. Even if a response result were reported, a single-group observation would describe outcomes in the treated group, not establish what would have happened under an alternative. No conclusion about comparative benefit can be drawn from the record.

The serious adverse-event percentages are safety summaries, not a measure of treatment efficacy. Their interpretation is limited by the missing event-level details and the unexplained difference between the enrollment entry and the adverse-event group counts. The record does not report deaths, but absence of a reported death result is not the same as a documented zero.

In general, clinical interpretation combines outcome magnitude, precision, study design, completeness of follow-up, and the relevance of the population and endpoint. Several of these components are not documented in the registry record. The appropriate conclusion is therefore limited: the registry describes the study design, regimen, response definition, and selected safety information, while the primary result and statistical analyses are not reported. This is not evidence that BMR did or did not control disease, and it is not a basis for treatment advice.

14. Why This Trial Matters Statistically

This trial illustrates why a clearly stated endpoint is not enough to interpret a clinical study result. The record gives a definition of complete response and a specified timeframe of 3 months, which identifies what the primary outcome was intended to capture. But without the response count, the number assessed, and an estimate of uncertainty, the endpoint cannot be quantified statistically.

The single-group design is also central to interpretation. A descriptive outcome can be useful for understanding what was observed in a treated group, but it does not estimate a treatment contrast against a concurrent comparator. The absence of a comparator is not a minor reporting detail: it determines which statistical questions the design can answer. Here, the registry does not support a direct comparison of BMR with another option.

The difference between enrollment and the adverse-event summary is a reminder that denominators need to be tied to specific outcomes. The record lists enrollment as 14 and the adverse-event group as 8 at risk and 8 affected. Without an explanation or the primary endpoint denominator, these counts cannot be combined or substituted for one another.

The entry also lists 3 outcome measures but 0 analyses. That distinction matters: outcome definitions describe what was measured, while analysis records explain how the measurements were summarized and interpreted. The record documents the former more fully than the latter. Statistical methods, missing-data handling, multiplicity procedures, and analysis populations are not reported.

Finally, the status is terminated, but the reason for termination is not reported in the registry record. Statistical interpretation should not infer a cause or a trial result from that status alone. The example underscores the value of complete outcome reporting, transparent denominators, and prespecified analysis descriptions when readers assess evidence from a small, single-group clinical study.

15. Limitations

• The posted summary statistics are the only data these results rest on; patient-level data, full protocols and statistical analysis plans are not available.
• Recalculated results are simple, unadjusted calculations from posted summaries. They do not replace the sponsor's prespecified analysis.

The primary limitation for interpretation is the absence of the primary outcome result. Although complete response at 3 months is defined, the registry record does not give the number of participants achieving complete response, the number assessed, a rate, or an uncertainty interval. The primary clinical question therefore cannot be answered quantitatively from the posted results.

The study is listed as single-group, with allocation not applicable and no masking. No comparator is recorded, so the study design does not yield a direct treatment contrast. The registry also does not report the details of outcome assessment, the analysis population, or whether response assessors were independent of treatment knowledge.

Enrollment is listed as 14, while the adverse-event summary records 8 at risk and 8 affected for both serious and other adverse events. The registry does not explain the relationship among these entries. The primary endpoint denominator is not reported, and outcome-specific follow-up or data availability cannot be assessed.

The study is marked terminated, but the reason for termination is not reported in the registry record. The record lists 3 outcome measures and 0 analyses; it does not describe the statistical plan, multiplicity handling, missing-data methods, or sensitivity analyses. The named time-to-progression outcome has no reported result. Deaths are not reported, which is not equivalent to a documented zero count.

The serious adverse-event terms and percentages provide only a limited view of safety. Event counts by term, timing, duration, recurrence, severity grading details, and attribution are not reported. The sample-size assumptions are identified as planning illustrations rather than the trial's design, and the record does not state the trial's sample-size justification. These limitations mean the registry entry supports description of the design and selected outcomes, but not a complete assessment of efficacy, precision, or safety.

16. Related Tutorials

17. Related Statistical Calculators

18. Sources

• ClinicalTrials.gov: Bendamustine, Mitoxantrone, and Rituximab (BMR) for Patients With Untreated High Risk Follicular Lymphoma — NCT00901927.
• Registry record last updated 2020-04-03; status last verified 2020-04.
• Results first posted 2020-04-03.
• Data retrieved from ClinicalTrials.gov on 2026-11-09.
• Group sizes, means, event counts and sponsor-reported p-values are reproduced as posted. Effect estimates, confidence intervals and p-values not attributed to the sponsor are independently calculated from the posted summary statistics.

19. Record Summary

The registry record describes a Phase II, single-group study of bendamustine, mitoxantrone, and rituximab for untreated high-risk follicular lymphoma. The sponsor is M.D. Anderson Cancer Center. The study is listed as terminated, with enrollment of 14, a start recorded as 2009-05, and primary completion recorded as 2016-01.

The primary outcome is complete response at 3 months, defined using International Working Group Criteria for Response for Non-Hodgkin's Lymphoma. Secondary outcomes are participants with adverse events and time to progression. The registry lists 3 outcome measures and 0 analyses. It reports selected serious adverse-event terms, but does not report the primary response result or time-to-progression result.

The design has no recorded comparator, and the statistical analysis plan, missing-data methods, analysis populations, and reason for termination are not reported in the registry record. The available information describes the study and its intended measures, but does not permit a quantitative interpretation of the primary efficacy result.